Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002266
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDSARC Patients
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDSARC Patients
Status:
COMPLETED
Status Verified Date:
1990-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare AS-101 dosing schedules once a week 3 times a week 5 times a week or 5 times per week on alternate weeks on the effect on clinical immunology and virus burden in AIDS or AIDS related complex ARC patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 753A-103-US | None | None | None |